Skip to main navigation Skip to search Skip to main content

Targeting Necrosis: Elastase-like Protease Inhibitors Curtail Necrotic Cell Death Both in Vitro and in Three in Vivo Disease Models

  • Boris Khalfin
  • , Alexandra Lichtenstein
  • , Amnon Albeck
  • , Ilana Nathan
  • Ben-Gurion University of the Negev
  • Soroka Medical Center

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Necrosis is the main mode of cell death, which leads to multiple clinical conditions affecting hundreds of millions of people worldwide. Its molecular mechanisms are poorly understood, hampering therapeutics development. Here, we identify key proteolytic activities essential for necrosis using various biochemical approaches, enzymatic assays, medicinal chemistry, and siRNA library screening. These findings provide strategies to treat and prevent necrosis, including known medicines used for other indications, siRNAs, and establish a platform for the design of new inhibitory molecules. Indeed, inhibitors of these pathways demonstrated protective activity in vitro and in vivo in animal models of traumatic brain injury, acute myocardial infarction, and drug-induced liver toxicity. Consequently, this study may pave the way for the development of novel therapies for the treatment, inhibition, or prevention of a large number of hitherto untreatable diseases.

Original languageEnglish
Pages (from-to)1510-1523
Number of pages14
JournalJournal of Medicinal Chemistry
Volume64
Issue number3
DOIs
StatePublished - 11 Feb 2021

Bibliographical note

Publisher Copyright:
© 2021 American Chemical Society. All rights reserved.

Funding

This study was supported by grants from the Israel Science Foundation, the Lyonel Israels Chair Foundation (I.N.), the Raoul Wallenberg Chair for Immunochemistry (A.A.), and ELA Pharma Ltd.

Funders
ELA Pharma Ltd
Israel Science Foundation

    Fingerprint

    Dive into the research topics of 'Targeting Necrosis: Elastase-like Protease Inhibitors Curtail Necrotic Cell Death Both in Vitro and in Three in Vivo Disease Models'. Together they form a unique fingerprint.

    Cite this